Short answer
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Stuart Essig returns as CEO effective May 1, 2026, succeeding Mojdeh Poul and retaining his Board chair role.
INTEGRA LIFESCIENCES HOLDINGS CORP 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Stuart Essig returns as CEO effective May 1, 2026, succeeding Mojdeh Poul and retaining his Board chair role
- Leadership change brings an experienced former CEO back to operational control after prior CEO service from 1997–2012
- Essig compensation includes $1.075M salary, 125% target bonus, and $8M initial equity awards
- Poul’s departure includes $566,526 cash payment plus up to $25,000 legal-fee reimbursement, subject to release
- Michael McBreen becomes Chief Commercial Officer with $660,000 salary, 90% target bonus, and $1M promotion equity award
Item EX-99.1 · Exhibit EX-99.1
- Stuart Essig appointed president and CEO effective May 1, 2026, while retaining chairman role
- Essig returns after serving as CEO from 1997 through early 2012, signaling continuity and deep institutional expertise
- Mojdeh Poul departs to pursue other opportunities, creating leadership-transition risk despite no planned CEO search
- Michael McBreen appointed newly created chief commercial officer, overseeing both divisions and global commercial operations
- Commercial reorganization targets stronger revenue growth, customer focus, and execution across Integra
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other INTEGRA LIFESCIENCES HOLDINGS CORP 8-K filings
Get the next IART 8-K as it lands
Follow IART for push alerts, or ask the research agent what this filing means.